Poziotinib in non-small-cell lung cancer patients with HER2 exon 20 mutations: A pooled analysis of randomized clinical trials

Non-small-cell lung cancer (NSCLC) harboring human epidermal growth factor receptor 2 (HER2) exon 20 mutant occurs in 3% of NSCLCs. Targeted agents for this population remain an unmet need. In this analysis, we pooled-analyzed the efficacy and safety of poziotinib, a novel tyrosine kinase inhibitor,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bi-Cheng, Kuang, Bo-Hua, Liu, Xin-Xiu, Lin, Guo-He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646509/
https://www.ncbi.nlm.nih.gov/pubmed/36343036
http://dx.doi.org/10.1097/MD.0000000000031337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646509/
https://www.ncbi.nlm.nih.gov/pubmed/36343036
http://dx.doi.org/10.1097/MD.0000000000031337

Ejemplares similares